Nan Tang
CEO Pulmongene
Nan Tang, M.D., Ph.D., is the founder and chairman of Pulmongene, and currently the Principal Investigator of National Institute of Biological Sciences (NIBS). Dr. Tang is an internationally renowned expert in pulmonary fibrosis and alveolar regeneration and has more than 20 years’ experience in investigating molecular and cellular drivers that promote alveolar regeneration. She established the first Idiopathic Pulmonary Fibrosis (IPF) mouse model that recapitulates human pathology and identified novel therapeutic targets of lung diseases.
Dr. Tang obtained her Ph.D. from the University of California, San Diego and completed her postdoctoral training at University of California, San Francisco. She is also trained as a physician and earned her medical degree from Medical School of Xi’an Jiaotong University.
Seminars
- AREG is a causal, upstream, epithelial-derived driver of fibrogenesis
- PMG1015 exhibited a well-tolerated safety profile with no dose limiting toxicities across three completed clinical studies
- In IPF, PMG1015 showed FVC stabilization and structural improvement on AI-quantified HRCT, supporting advancement into a global 52-week study